21Nov 2022
Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study

Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study

This is the most extensive multicentre, observational study conducted in the UK, demonstrating an overall incidence of bullous cutaneous irAEs associated with CPI of 0·3%. Clinical presentation may vary, with pruritus and non‐bullous variants appearing similar to other cutaneous toxicities. Time to onset appears later than with other cutaneous toxicities (12 months) and can occur after discontinuation of therapy. Therefore, interruption of CPI is often needed. The study demonstrates this occurs mainly in men and older age groups and is associated with BRAF wildtype in MM patients. Clinicians need to recognize this condition promptly so early optimal management is initiated to reduce interruptions to CPI and improve overall patient outcomes and tumour response.

  • #dermatology

Like

Save

Share